Mauna Kea Technologies SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Mauna Kea Technologies SAS Announces Cellvizio Optical Biopsies Study Results
Mauna Kea Technologies SAS announced a new study on the use of a Cellvizio optical biopsy to diagnose cancerous stomach tumors. The study was completed at the Soonchunhyang University Hospital Gastrointestinal Cancer Center in Seoul, Korea. Patients enrolled in the study underwent an optical biopsy prior to endoscopic resection of the cancerous tissue in the stomach lining previously diagnosed by endoscopic biopsy. The overall accuracy of the optical biopsy diagnosis was compared with endoscopic resection. The overall accuracy for the diagnosis of cancerous lesions in the stomach lining was 91.7% for optical biopsies and 85.2% for conventional biopsies. The combined accuracy of conventional endoscopic biopsies and optical biopsies was 98.1%.
Latest Developments for Mauna Kea Technologies SA
- Mauna Kea Technologies SA regulatory clearance from U.S. FDA for New Cellvizio System Functioning in a near Infrared Wavelength
- Mauna Kea Technologies receives regulatory approval for Cellvizio in Japan
- Mauna Kea Technologies installs first three Cellvizio systems and obtains key regulatory clearances in Brazil
- Mauna Kea Technologies obtains FDA clearance for Cellvizio in urology
- Share this
- Digg this